Micafungin
- Generic Name
- Micafungin
- Brand Names
- Mycamine
- Drug Type
- Small Molecule
- Chemical Formula
- C56H71N9O23S
- CAS Number
- 235114-32-6
- Unique Ingredient Identifier
- R10H71BSWG
- Background
Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
- Indication
Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been...
- Associated Conditions
- Abscesses, Aspergillosis, Candidemia, Candidiasis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Acute disseminated Candidiasis
- Associated Therapies
- -
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 56
- Registration Number
- NCT06413056
- Locations
- 🇪🇬
Ain Shams University Hospitals, Cairo, Abbassia, Egypt
Antimicrobial Revision in Persistent Febrile Neutropenia
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT05784844
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Evaluate Bioequivalence of Micafungin (50mg/Vial)
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05496725
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin
- Conditions
- Interventions
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- Fadoi Foundation, Italy
- Target Recruit Count
- 14
- Registration Number
- NCT03906916
- Locations
- 🇮🇹
Ente Ospedaliero Galliera, Genova, Italy
🇮🇹Ospedale "Antonio Cardarelli, Napoli, Italy
🇮🇹Ospedale "S. Anna", Como, Italy
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03421002
- Locations
- 🇮🇹
Site IT39002, Rome, Italy
🇮🇹Site IT39001, Rome, Italy
Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03174457
- Locations
- 🇨🇳
Site TW601, Taipei, Taiwan
🇨🇳Site TW604, Taipei, Taiwan
🇰🇷Site KR401, Seoul, Korea, Republic of
Micafungin Pharmacokinetics in Obese Patients
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT03102658
- Locations
- 🇳🇱
St Antoniusziekenhuis, Nieuwegein, Netherlands
🇳🇱Radboudumc CRCN, Nijmegen, Netherlands
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 2555
- Registration Number
- NCT02678598
Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 10
- Registration Number
- NCT02651038
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02646774
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.